Cholesterol-lowering efficacy ofLactobacillus plantarumCECT 7527, 7528 and 7529 in hypercholesterolaemic adults

Abstract

Previous studies have indicated that supplementation with probiotic bacteria may improve lipid metabolism. The present study was aimed at investigating the effects of a mixture of three strains of Lactobacillus plantarum (CECT 7527, CECT 7528 and CECT 7529) on cholesterollowering efficacy in hypercholesterolaemic patients. A total of sixty volunteers (thirty participants in the placebo group and thirty counterparts in the L. plantarum group), aged 18-65 years old, participated in a controlled, randomised, double-blind trial. The study group received one capsule daily containing 1·2 £ 10 9 colony-forming units of Lactobacillus strains in a unique dose; the placebo group consumed the same product without bacteria for 12 weeks. A significant reduction of 13·6 % in plasma total cholesterol (TC) levels was observed after 12 weeks of consumption in the L. plantarum group when compared with the placebo group. The lipidic outcomes were also analysed based on TC values at baseline: low initial values (LIV, 2000 -2500 mg/l) v. high initial values (HIV, 2510 -3000 mg/l). In the HIV group, the L. plantarum treatment showed a reduction after 12 weeks of consumption compared with the placebo group in TC, LDL-cholesterol (LDL-C) and oxidised LDL-C (17·4, 17·6 and 15·6 %, respectively). In the LIV, the L. plantarum treatment only showed a reduction after 12 weeks of consumption when compared with the placebo group in TC (9·4 %). The present results showed that the biofunctionality of L. plantarum (CECT 7527, CECT 7528 and CECT 7529) is proportional to the cardiovascular risk of the patient, having a better effect in patients with higher levels of cholesterol.

Lactobacillus plantarumCECT 7527, 7528 and 7529: probiotic candidates to reduce cholesterol levels

“…The results of this in vitro assay were confirmed in a controlled, randomised, double‐blind trial in 60 volunteers who were divided into two groups (one group received one capsule daily during 12 weeks containing 1.2 × 10 9 cfu of a mixture of Lactobacillus plantarum CECT 7527, 7528 and 7529 strains, and the second group received a placebo). A significant reduction of 13.6% in plasma total cholesterol levels was observed after 12 weeks of consumption in the L. plantarum group when compared with the placebo group …”

“…A significant reduction of 13.6% in plasma total cholesterol levels was observed after 12 weeks of consumption in the L. plantarum group when compared with the placebo group. 24…”

Hypocaloric diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients - a randomized double-blind placebo-controlled pilot study

“…Functional properties of L. plantarum TENSIA include antimicrobial activity; production of polyamines and nitric oxide; and moderate anti-oxidative ability [20]. Several studies by different investigators have described the beneficial effects of the consumption of the species L. plantarum on human physiology [31,36,37]. …”

Lactobacillus plantarum CUL66 can impact cholesterol homeostasis in Caco-2 enterocytes

“…The lack of evidence correlating cholesterol consumption with serum cholesterol levels (Christie, 2015) has raised questions about the validity of a cholesterol restricted diet as a preventative measure suggesting that lifestyle changes alone cannot reduce susceptibility to the development of CVD. There is now growing evidence that some probiotic organisms (components of the indigenous microbiota) have the capacity to impact multiple aspects of the cholesterol metabolism of the host (Gorenjak et al, 2014;Huang et al, , 2013Pereira and Gibson, 2002a,b;Yoon et al, 2011Yoon et al, , 2013 resulting in reduced serum cholesterol levels (Fuentes et al, 2013;Mann, 1974;Pereira and Gibson, 2002b;Rerksuppaphol and Rerksuppaphol, 2015) and positive CVD-related outcomes (Sun and Buys, 2015).…”